Obermatt
See Similar Stocks →

Personalis

NMQ:PSNL · US71535D1063
Life Sciences Tools & ServicesSmall

360

8
Profit price76
Owner Earnings Yield1
Dividend Yield1
Price/Sales68
EV / Gross Profit3
Price/Book26
Return on Capital4
Cash Return on Capital11
Return on Equity16
EBIT Margin6
Gross Profitability8
Accruals3
Owner Earnings Margin6
Sales growth63
Profit growth50
Reinvestment87
Price momentum77
Debt load48
Refinancing79
Debt Payback1
Liquidity23
Analyst ratings22
Opinion Changes50
Price Target Upside40
Market mood49
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Personalis doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2011
Employees266
Websitepersonalis.com
ISINUS71535D1063
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsHealth DiagnosticsOncologyBiotechnologyHealth Care

Description

Personalis, Inc. (Personalis) develops, markets, and sells advanced cancer genomic testing services. The company's testing services are utilized by pharmaceutical companies for translational research, biomarker discovery, the development of personal…

Analysis

Story stock

Personalis, Inc. is a story stock: the narrative is ambitious and the price reflects it, but the underlying numbers are weak.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 4/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
91
2023202420252026

All-time high

91

Jun 2026

All-time low

41

Jan 2025

Average rank

72

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
68
35
91
38
Price/Earnings
78
88
88
30
Price/Book
26
43
88
94
Dividend Yield
1
1
1
1
Value (overall)
93
28
85
71

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Personalis with its peers
Zentalis Pharmaceuticals
NMQ:ZNTL
12
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Adaptive Biotechnologies
NSQ:ADPT
20
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Xbiotech
NSQ:XBIT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Elicio Therapeutics
NAQ:ELTX
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Galectin Therapeutics
NAQ:GALT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Repare Therapeutics
NSQ:NULL
—
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →